EGFR and non-small cell lung carcinoma: Multiple phase III trials have validated that first-generation EGFR-TKIs (gefitinib, erlotinib, icotinib) and second-generation EGFR-TKIs (afatinib, dacomitinib) significantly improves objective response rate (ORR) and progression-free survival (PFS) compared to platinum-based chemotherapy in treatment-naïve NSCLC patients with EGFR mutations (Fukuoka et al., 2011; Rosell et al., 2012; Sequist et al., 2013).